Publications by authors named "J HOPPER"
Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed.
Methods: We explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer diagnosis, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 223,316 females without breast cancer diagnosis from the UK Biobank.
Menopausal hormone therapy (MHT) users are at increased breast cancer (BC) risk and decreased colorectal cancer (CRC) risk compared with never users, but these opposing associations might differ by familial risk of BC and CRC. We harmonized data from three cohorts and generated separate BC and CRC familial risk scores (FRS) based on cancer family history. We defined moderate/strong family history as FRS ≥ 0.
View Article and Find Full Text PDFArtificial intelligence (AI) is enabling us to delve deeply into the information inherent in a mammogram and identify novel features associated with high risk of a future breast cancer diagnosis. Here, we discuss how AI is improving mammographic density-associated risk prediction and shaping the future of screening and risk-reducing strategies.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the impact of wildfire-related particulate matter (PM) on epigenetic aging, revealing a link between exposure levels and increased biological aging.
- For every 1 µg/m increase in annual wildfire PM, there was an acceleration of 0.25 years in GrimAge1 and 0.36 years in GrimAge2, indicating faster aging impacts.
- Older adults, individuals with smoking or alcohol backgrounds, and those in rural areas are particularly affected, highlighting the health risks associated with wildfire smoke exposure.
Article Synopsis
- Women with BRCA1 and BRCA2 pathogenic variants may experience surgical menopause after RRSO, with previous studies showing increased depressive and anxiety symptoms at 6 and 12 months post-surgery.
- A controlled study tracking 59 women undergoing RRSO and 91 comparison women found that, at 24 months, depressive and anxiety symptoms were not significantly elevated and did not differ between the two groups. However, symptoms at 12 months strongly predicted outcomes at 24 months.
- The study concluded that while symptoms don't seem to escalate after 24 months, persistent symptoms observed at 12 months can indicate ongoing issues, with no significant impact from Menopausal Hormone Therapy on mental health.